Pep2Tango Therapeutics
Pre-clinicalNext generation anti-obesity unimolecular multi-agonist peptides with superior weight loss, preservation of muscle mass, and improved tolerability
Founded
2021
Focus
Small Molecules
About
Next generation anti-obesity unimolecular multi-agonist peptides with superior weight loss, preservation of muscle mass, and improved tolerability
Funding History
1Total raised: $75M
Seed$75MMubadala CapitalOct 15, 2023
Company Info
TypePrivate
Founded2021
LocationCambridge, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile